Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FENC 
Fennec Pharmaceuticals Inc (FENC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: FENC (1-star) is a SELL. SELL since 2 days. Simulated Profits (-10.65%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $14
1 Year Target Price $14
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.04% | Avg. Invested days 29 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 229.65M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 5 | Beta 0.64 | 52 Weeks Range 3.96 - 9.92 | Updated Date 10/19/2025 |
52 Weeks Range 3.96 - 9.92 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -36.15% | Operating Margin (TTM) -28.31% |
Management Effectiveness
Return on Assets (TTM) -11.19% | Return on Equity (TTM) -1005.59% |
Valuation
Trailing PE - | Forward PE 17.06 | Enterprise Value 268579006 | Price to Sales(TTM) 6.9 |
Enterprise Value 268579006 | Price to Sales(TTM) 6.9 | ||
Enterprise Value to Revenue 8.06 | Enterprise Value to EBITDA 20.27 | Shares Outstanding 27831698 | Shares Floating 14440477 |
Shares Outstanding 27831698 | Shares Floating 14440477 | ||
Percent Insiders 16.27 | Percent Institutions 57.63 |
Upturn AI SWOT
Fennec Pharmaceuticals Inc
Company Overview
History and Background
Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for pediatric oncology. Founded in 1996 and located in Research Triangle Park, NC. Its initial focus was on animal health before pivoting to human therapeutics. Its evolution has centered on addressing unmet needs in pediatric cancer treatment.
Core Business Areas
- Pediatric Oncology: Fennec's core business revolves around developing and commercializing therapies to improve outcomes for children with cancer, specifically focused on preventing ototoxicity associated with platinum-based chemotherapy.
Leadership and Structure
Dr. Rosty Raykov is the Chief Executive Officer. The company has a board of directors overseeing strategic direction. The structure involves research and development, clinical operations, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- PEDMARK: PEDMARK (sodium thiosulfate) is Fennec's primary product, designed to reduce the risk of ototoxicity (hearing loss) associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic solid tumors. While precise market share data is not readily available, PEDMARK addresses a significant unmet need in pediatric oncology. Competitors in supportive care for chemotherapy side effects include companies providing anti-nausea medication and other supportive therapies such as Acacia Pharma (ACP.L) with Barhemsys.
Market Dynamics
Industry Overview
The pharmaceutical industry is continuously evolving, with a growing focus on oncology and precision medicine. The pediatric oncology segment is particularly focused on developing less toxic and more effective treatments. The pharmaceutical industry is a large and competitive market with large R&D budgets.
Positioning
Fennec is positioned as a specialty pharmaceutical company addressing a specific unmet need in pediatric oncology, offering a unique product to mitigate chemotherapy-induced ototoxicity. It has a competitive advantage with PEDMARK.
Total Addressable Market (TAM)
The TAM for PEDMARK is estimated based on the number of children undergoing cisplatin chemotherapy annually. Estimates suggest the market to be worth several hundred million USD. Fennec is well positioned in the ototoxicity market with PEDMARK.
Upturn SWOT Analysis
Strengths
- FDA approved product PEDMARK
- Focus on unmet need in pediatric oncology
- Established partnerships and distribution channels
- Specialized expertise in ototoxicity prevention
Weaknesses
- Reliance on a single product
- Limited commercial infrastructure
- Small market capitalization
- Dependence on successful marketing and sales
Opportunities
- Expansion of PEDMARK indications to other cancers
- Development of new therapies for pediatric oncology
- Strategic partnerships and collaborations
- Geographic expansion to international markets
Threats
- Competition from alternative therapies or generics
- Regulatory hurdles and changes in guidelines
- Pricing pressures and reimbursement challenges
- Clinical trial failures or adverse events
Competitors and Market Share
Key Competitors
- ACAD
- TEVA
Competitive Landscape
Fennec has a unique product in PEDMARK but faces competition from companies offering supportive care therapies for chemotherapy side effects. Its competitive advantage lies in its targeted approach to ototoxicity prevention.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial success and regulatory approvals.
Future Projections: Future growth is projected based on PEDMARK sales, market penetration, and potential new indications.
Recent Initiatives: Recent initiatives include launching PEDMARK commercially and expanding its market reach.
Summary
Fennec Pharmaceuticals is a developing biopharmaceutical company with a focus on pediatric oncology. PEDMARK provides a vital therapy to children undergoing cancer treatment. While reliance on one product and lack of commercial infrastructure are some of its challenges, its ability to expand PEDMARKu2019s indications, develop new therapies, and establish collaborations are its opportunities. The key is to scale up sales of PEDMARK successfully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings, Investor presentations, Analyst reports, News articles
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share data is based on estimations and assumptions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fennec Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Research Triangle Park, NC, United States | ||
IPO Launch date 2001-06-05 | CEO & Director Mr. Jeffrey S. Hackman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://fennecpharma.com |
Full time employees 32 | Website https://fennecpharma.com | ||
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.